Sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation of the bladder: a case report

Recep Bedir
Department of Pathology, Recep Tayyip Erdogan University, Medical Faculty, Rize, Turkey

Abstract

Sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation of the urinary bladder is a rare tumor. This tumor, known as carcinosarcoma has a poor prognosis. The present study reports a rare case of sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation in the bladder of a 71-year-old man.

Keywords

Bladder; Sarcomatoid Carcinoma; Chondrosarcomatous Differentiation


Corresponding Author: Recep Bedir, Department of Pathology, Recep Tayyip Erdogan University, Medical Faculty, Rize, Turkey.
T.: +90 4642130491 GSM: +905057331695 E-Mail: bedirecep@gmail.com
ORCID ID: https://orcid.org/0000-0001-8247-3781

522 | The Annals of Clinical and Analytical Medicine
Introduction
Sarcomatoid urothelial carcinoma is a very rare variant of urothelial carcinoma and it is generally detected in the bladder [1]. It constitutes 0.2-0.6% of all the histological subtypes of urothelial carcinomas found in bladder [2]. The malign heterologous elements such as chondrosarcoma and osteosarcoma may accompany these tumors, which are also known as carcinosarcoma [3]. The prognosis of these tumors having an aggressive course is worse than other urothelial carcinomas [4]. In the present study, we present a 71-year-old male patient’s sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation detected in bladder transurethral resection (TUR) material which is rarely seen.

Case Report
A 71-year-old male patient applied to our clinic with the complaint of hematuria for 15-20 days. In computed tomography (CT) imaging, a mass infiltrating the bottom-right edge of the urethra, extending towards adjacent fatty tissues, and having 8x4cm size was found in the right posterior wall of the bladder. The patient underwent TUR. In the macroscopic analysis of TUR material with 15x10x7cm size, the high-grade urothelial carcinoma foci consisting of papillary structures and the sarcomatoid zones showing differentiation towards chondrosarcoma consisting of spindle mesenchymal cells with the apparent nucleolus and large hyperchromatic nucleus, and having a pleomorphic appearance with highly mitotic activity were observed (Figure 1-3). In addition, the tumor was observed an undifferentiated element composed of small cells (Figure 4). No invasion analysis could be performed since no muscularis propria was observed in the tumor. In immunohistochemical analysis, the positive staining with both cytokeratin 7 (CK7) and vimentin were observed in sarcomatoid areas and positive staining with S-100 in chondrosarcomatous areas. Based on these findings, the case was diagnosed with invasive sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation. Since the patient didn’t accept the surgical therapy, he received chemotherapy for only 3 months and then died 1 year later because of widespread metastases. The written informed consent was obtained from the patient before the aforementioned work was carried out.

Discussion
Sarcomatoid urothelial carcinoma is a different histologic variant of urothelial carcinoma and the term “invasive urothelial carcinoma, sarcomatoid variant” was preferred in the 2004 World Health Organization Classification Tumors of the Urinary System [5]. The risk of metastasis is high in urothelial carcinomas with sarcomatoid differentiation and the most frequently seen metastases are those in bones, liver, lung, and lymph nodes [6]. The large majority of these tumors are histologically high-grade [7]. In sarcomatoid carcinomas, the metaplastic changes such as chondroid and osseous metaplasia or the more aggressive histological findings such as pseudo-sarcomatous stroma may be seen [4]. In these tumors, the epithelial component consists of urothelial carcinoma, urothelial carcinoma in situ, small-cell carcinoma, adenocarcinoma, and squamous cell carcinoma, whereas the sarcomatous component consists of leiomyosarcoma, chondrosarcoma, and osteosarcoma [5]. The differential diagnosis of these tumors includes the pseudo-sarcomatous stromal reaction with low mitotic activity and minimal atypia but deficit in apparent malignity criteria.

In these tumors having bad prognosis resistant to radiotherapy, the main therapy option is surgical resection and it is recommended to perform total cystectomy. The adjuvant radiotherapy and chemotherapy were observed to have no positive effect on the prognosis [7-9]. Since he denied surgical therapy, our patient received only the chemotherapy.

Figure 1. Tumor showing epithelial and sarcomatoid component (H&Ex100)
Figure 2. Tumor showing sarcomatoid carcinoma component with chondrosarcomatous differentiation (H&Ex200)
Figure 3. Tumor showing well-differentiation chondrosarcomatous areas (H&Ex200)
In conclusion, understanding the sarcomatoid urothelial carcinoma is important from therapeutic and prognostic aspects. These tumors should be accepted as high-grade invasive urothelial carcinoma with a high level of sarcomatous differentiation, which may include malign heterologous components such as chondrosarcoma. The pseudosarcomatous stromal reaction, which may be confused with these tumors in the histopathological analysis, should be kept in mind.

**Scientific Responsibility Statement**

The authors declare that they are responsible for the article's scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.

**Animal and human rights statement**

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No animal or human studies were carried out by the authors for this article.

**Conflict of interest**

None of the authors received any type of financial support that could be considered potential conflict of interest regarding the manuscript or its submission.

**References**

6. Johnin K, Kadowaki T, Kushima M, Ushida H, Koizumi S, Okada Y. Primary het-